Eleven Biotherapeutics Inc. (EBIO) Trading 6.3% Higher
Eleven Biotherapeutics Inc. (NASDAQ:EBIO) shares traded up 6.3% during mid-day trading on Monday . The company traded as high as $5.17 and last traded at $5.08, with a volume of 1,014,774 shares changing hands. The stock had previously closed at $4.78.
The company’s market cap is $76.81 million. The stock’s 50-day moving average price is $3.58 and its 200 day moving average price is $1.62.
Eleven Biotherapeutics (NASDAQ:EBIO) last issued its quarterly earnings results on Friday, August 12th. The biopharmaceutical company reported ($0.33) EPS for the quarter. On average, analysts predict that Eleven Biotherapeutics Inc. will post ($1.75) earnings per share for the current year.
In related news, major shareholder Boxer Capital, Llc sold 1,042,000 shares of the business’s stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $2.74, for a total transaction of $2,855,080.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.